A standard lipid panel is a reasonable starting point, but it can leave a serious question unanswered: how many particles are actually driving risk, how much of that is inherited, and how much silent inflammation is in the mix. Three markers, ApoB, Lp(a), and hs-CRP, help fill those gaps, and they are worth banking before you build a long-horizon plan.
Why the standard panel can under-read your risk
Most people have seen the familiar four: total cholesterol, LDL cholesterol (LDL-C), HDL cholesterol, and triglycerides. That panel estimates the *cholesterol mass* your LDL particles are carrying. It does not directly count the *particles* themselves, and it says nothing about your inherited lipoprotein(a) burden or your background inflammatory tone.
That matters because atherosclerosis is, mechanistically, a particle problem. Apolipoprotein B (ApoB)-containing lipoproteins enter and get retained in the arterial wall, and the number of those particles tracks disease risk closely [1]. Two people can share an identical LDL-C number while carrying very different particle counts. If you are going to invest in a thirty-year plan, you want to see the picture the standard panel can blur.
ApoB: counting the particles, not just the cholesterol
Every atherogenic lipoprotein (LDL, VLDL, IDL, and Lp(a)) carries exactly one ApoB molecule. So an ApoB measurement is effectively a direct count of the particles most implicated in arterial plaque, cutting across the categories a lipid panel separates [1]. The 2018 ACC/AHA cholesterol guideline and a 2019 European Atherosclerosis Society consensus recognize ApoB as a risk-enhancing measurement that can reveal residual risk when LDL-C looks reassuring, particularly in people with high triglycerides, metabolic syndrome, or diabetes [2][3].
The practical value: ApoB can flag a mismatch. If your LDL-C reads "fine" but your particle count is elevated, that discordance is exactly the signal a careful baseline is meant to catch. It is a measurement to review with a provider, not a number to self-treat.
Lp(a): the inherited marker you measure once
Lipoprotein(a) is an LDL-like particle with an extra protein attached. Your level is roughly 80 to 90 percent genetically determined, set early in life, and largely stable regardless of diet or exercise [4]. That is why guidelines increasingly suggest measuring it at least once in adulthood: it is a distinct, heritable axis of risk that behavior does not meaningfully move [3][4].
Elevated Lp(a) is common. Population data suggest roughly one in five people carry levels associated with increased cardiovascular risk [4]. Because it is inherited and stable, a single measurement usually tells the story for a lifetime, which makes it an efficient thing to bank once at baseline. Knowing an elevated Lp(a) early changes how aggressively other, modifiable risks tend to be watched over decades.
Source: [4] Lipoprotein(a) in Clinical Practice: A Scientific Statement (National Lipid Association)
hs-CRP: reading the inflammatory background
High-sensitivity C-reactive protein (hs-CRP) is a blood marker of low-grade inflammation. Because atherosclerosis is partly an inflammatory process, hs-CRP adds a layer that lipid measurements alone do not capture [5]. The CDC/AHA scientific statement describes commonly referenced hs-CRP interpretation bands for cardiovascular risk stratification: below 1.0 mg/L (lower relative risk), 1.0 to 3.0 mg/L (average), and above 3.0 mg/L (higher) [5].
One caveat worth understanding: hs-CRP is nonspecific. A recent infection, injury, or acute illness can transiently raise it, which is why interpretation belongs with a provider who can put a single value in context and, when appropriate, repeat it. Read correctly, it helps distinguish a quiet arterial environment from an inflamed one.
mg/L · marker = Common upper reference
Source: [5] Markers of Inflammation and Cardiovascular Disease: AHA/CDC Scientific Statement
Reading the three together
The point of banking all three is that they describe different, non-redundant dimensions: ApoB quantifies the atherogenic particle burden you can influence, Lp(a) captures inherited particle risk you generally cannot, and hs-CRP reflects the inflammatory context those particles operate in [1][3][5]. A baseline that includes all three gives an independent provider a far more complete map than a lipid panel alone, and it establishes the reference point every future measurement is compared against.
This is also where discipline beats novelty. These are established, guideline-referenced markers, not exotic add-ons. For anyone screening for a program that treats longevity as real medicine rather than a membership perk, the rigor of the baseline is a useful signal.
What a provider actually does with them
Measurements are inputs, not conclusions. An independent, licensed provider reviews these values alongside your full history, blood pressure, family history, and other labs to build an individualized picture. The markers inform a conversation about risk and monitoring cadence. They do not, on their own, prescribe anything. Any decision about therapy, lifestyle direction, or follow-up testing is made by that provider based on your complete clinical context.
This article is educational and is not medical advice, diagnosis, or a recommendation to take any specific medication. Interpretation of your labs should happen with a licensed clinician who knows your history.
Where Velri fits
Velri is a technology and coordination company, not a medical practice. Velri does not provide medical care and employs no physicians. What Velri coordinates is the workflow around a deliberate baseline: helping arrange laboratory testing (which can include markers like ApoB, Lp(a), and hs-CRP), connecting you with an independent, physician-led Provider Group for a visit where those results are reviewed in context, and, if a provider independently determines it is appropriate and writes a prescription, coordinating fulfillment through an independent, licensed pharmacy.
A prescription is never guaranteed. Whether any treatment is appropriate is decided solely by an independent licensed provider. If compounded medications are ever part of a provider's plan, note that compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality; compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug; and availability varies by state.
Velri's coordinated services are starting in Nevada, with additional states rolling out over time. Data handling and discretion are treated as core to the experience, not an afterthought. The goal is simple: a clean, well-documented baseline reviewed by an independent clinician, so your longevity thinking rests on real numbers rather than guesswork.
